AEON BIOPHARMA INC
AEONNYSE AMERICANTrading Snapshot
- Day Range
- $0.24 – $0.27
- 52-Week Range
- $0.18 – $1.45
- Volume (shares)
- 729,250
- Avg Volume (shares)
- —
- Shares Outstanding
- 37.2M
- Next Earnings
- 2026-11-13
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.58
- Dividend Yield
- —
- Dilution (1yr)
- +2079.9%
AEON BIOPHARMA INC
AEON
StockOtter · stockotter.spaceAbout AEON BIOPHARMA INC
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
AEON STRATEGIES LTD. Provides Update on Anticipated Late Filing of Annual Financial Statements
TORONTO, ONTARIO – TheNewswire - October 27, 2026 — AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB: CLDVF) (FSE: WQ40) (the “ Company ” or “ Aeon ”) provides an update to its news release dated O
Aeon Strategies Ltd. Announces Anticipated Late Filing of Annual Financial Statements and Application for Management Cease Trade Order
TORONTO, ONTARIO – TheNewswire - October 23, 202 6 - AEON STRATEGIES LTD. (formerly Cloud3 Ventures Inc.) (CSE: AEON) (OTCQB:CLDVF)(FSE:WQ40) (the “ Company ” or “ Aeon ”) announces that it expects to be unable to file i
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP ph
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence supporti
AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) fo
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
- Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-45